We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
The Evolving Role of MET TKIs in NSCLC
Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Jyoti Patel, MD
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Nadia Harbeck, MD, PhD
Maximizing Adherence and Persistence via Patient Engagement
Hope S. Rugo, MD, FASCO
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Treatment Intensification in HR+/HER2- EBC: Who and When?
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
Interprofessional Coordination of Adverse Event Management
Recent updates from adjuvant trials in HR+/HER2- EBC
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
John H. Stone, MD, MPH
Emanuel Della Torre, MD, PhD
Yoh Zen, MD, PhD, FRCPath
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Yasmin Genevieve Hernandez-Barco, MD
Avinash Kambadakone-Ramesh, MD, DNB, FRCR
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Emma Culver, BSc, MD, PhD, FRCP
Louisa Catherine Firmin, MBChB, MRCS, FRCR
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education